DGIdb - STAVUDINE Drug Record

STAVUDINE chembl:CHEMBL991 Approved

Alternate Names:

ZERIT XR
STAVUDINE
D-4T
BMY-27857
SANILVUDINE
ZERIT
NSC-163661
D4T
3'-DEOXY-2'-THYMIDINENE
STAVUDIN
ESTAVUDINA
2',3'-DIDEHYDRO-3'-DEOXYTHIMIDINE
1-(2,3-DIDEOXY-BETA-D-GLYCERO-PENT-2-ENOFURANOSYL)THYMINE
STV
STAVUDINUM
rxcui:59763
drugbank:00649
chemidplus:3056-17-5
pubchem.compound:18283
chembl:CHEMBL991

Drug Info:

(2 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Moketla MB et al., 2018, Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy., PLoS One
Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J
Lavie et al., 2004, Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase., Mini Rev Med Chem
Perno et al., 1989, Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine., J. Exp. Med.
Chew CS et al., 2011, Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients., Tissue Antigens
Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.
Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses

STAVUDINE SAMHD1

Interaction Score: 8.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30273369

Sources:
PharmGKB
STAVUDINE DTYMK

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15134538

Sources:
NCI
STAVUDINE TNFRSF1B

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9430255

Sources:
NCI
STAVUDINE CXCL10

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11141242

Sources:
NCI
STAVUDINE CSF2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2538549

Sources:
NCI
STAVUDINE CYP2B6

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23089673

Sources:
PharmGKB
STAVUDINE HLA-B

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
STAVUDINE TNF

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20887379

Sources:
PharmGKB
STAVUDINE PLK1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
STAVUDINE CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
STAVUDINE CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
STAVUDINE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
STAVUDINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
STAVUDINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

NCI: STAVUDINE

Version: 14-September-2017

Alternate Names:

C1428 NCI drug code

Drug Info:

Publications:

Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses

NCI: D4T

Version: 14-September-2017

Alternate Names:

C1428 NCI drug code

Drug Info:

Publications:

Perno et al., 1989, Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine., J. Exp. Med.

Lavie et al., 2004, Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase., Mini Rev Med Chem

Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.

DTC: STAVUDINE
- Version: 02-September-2020
Alternate Names:

CHEMBL991 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: stavudine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Moketla MB et al., 2018, Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy., PLoS One

Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J

Chew CS et al., 2011, Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients., Tissue Antigens

TTD: Stavudine
- Version: 2020.06.01
Alternate Names:

D0Z8EX TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL991
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

STAVUDINE Drug Record

STAVUDINE chembl:CHEMBL991 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30273369

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15134538

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9430255

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11141242

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2538549

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23089673

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20887379

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

NCI: STAVUDINE

Alternate Names: C1428 NCI drug code

Drug Info:

Publications: Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses

NCI: D4T

Alternate Names: C1428 NCI drug code

Drug Info:

DTC: STAVUDINE

Alternate Names: CHEMBL991 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: stavudine

Alternate Names:

Drug Info:

TTD: Stavudine

Alternate Names: D0Z8EX TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL991

Interaction Types & Directionality:

n/a

PMIDs:
30273369

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15134538

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9430255

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11141242

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2538549

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23089673

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20887379

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

C1428 NCI drug code

Publications:

Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses

Alternate Names:

C1428 NCI drug code

Alternate Names:

CHEMBL991 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D0Z8EX TTD Drug ID